Molecular NeuroImaging
27
0
0
22
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
14.8%
4 terminated/withdrawn out of 27 trials
84.6%
-1.9% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 22 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (27)
A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease
Role: collaborator
Assessment of the Effect of Sertaline on the Specific Binding of 123-I MZINT in Healthy Subjects
Role: collaborator
Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition
Role: collaborator
Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome
Role: collaborator
Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET
Role: lead
Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
Role: lead
Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects
Role: collaborator
Phase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects
Role: lead
Assessment of the Biodistribution and Safety of [18F]MNI-968 in Healthy Subjects
Role: lead
Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
Role: lead
Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease
Role: lead
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
Role: lead
ALTROPANE® SPECT Imaging in Patients With Parkinson Disease
Role: lead
Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to HVs.
Role: lead
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
Role: lead
Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty
Role: collaborator
Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families
Role: collaborator
Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease
Role: collaborator
Biodistribution and Safety of a Radiopharmaceutical in Healthy Subjects
Role: collaborator
Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain
Role: collaborator